Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthieu Texier

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Nature|April 29, 2026
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1Lambros Tselikas, Sandrine Susini, Matthieu Texier, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.
Nature|April 29, 2026
Safety and efficacy of intratumoural anti-CTLA4 with intravenous anti-PD1Lambros Tselikas, Sandrine Susini, Matthieu Texier, et al.
Journal of Experimental & Clinical Cancer Research : CR|July 6, 2022
Safety, recommended dose, efficacy and immune correlates for nintedanib in combination with pembrolizumab in patients with advanced cancersCapucine Baldini, Francois-Xavier Danlos, Andreea Varga, et al.
Cancer Discovery|January 20, 2023
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural MesotheliomaFrançois-Xavier Danlos, Matthieu Texier, Bastien Job, et al.
Pageof 3